• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Could 60-Day Percutaneous PNS Treatment Lead to Sustained Pain Relief by Reconditioning the CNS?

April 1, 2021

Authors: Chief Scientific Officer Josh Boggs, PhD; Senior Research Manager, Nate Crosby

In a recently published review, a novel pain mechanism theory was proposed that indicates short-term percutaneous PNS may lead to sustained pain relief by reconditioning the CNS, potentially obviating the need for permanently implanted systems.

Drs. Timothy Deer, Sam Eldabe, Steven Falowski, Marc Huntoon, Peter Staats, Nathan Crosby, and Isaac Cassar and I proposed potential mechanisms by which PNS may provide sustained pain relief by reconditioning the CNS. This review was conducted to explore the potential theories and mechanisms by which percutaneous PNS may produce the sustained pain relief that is being reported in multiple clinical studies. An additional goal was to generate discussion in the clinical and scientific communities that may lead to studies that further explore the possibility of modulating a centrally-maintained pain state by providing peripheral input through PNS. Below we dive more specifically into the findings of this research related to the cortical effects of short-term PNS and conventional PNS.

PNS with Remote Selective Targeting Can Produce Sustained Relief

Remote selective targeting is an approach to PNS that is made possible through multiple factors, including open-coiled leads with a long monopolar electrode, waveform design, and use of a system that enables lead placement remote from the nerve (e.g., 0.5-3 cm), that collectively enable more selective, preferential activation of targeted non-pain sensory fibers.

The collective review of numerous publications by Deer et al. found that remote selective targeting has a greater potential to produce beneficial reconditioning of maladaptive CNS changes compared to conventional stimulation strategies, ultimately helping patients avoid the need for a permanently implanted PNS system.

60-day PNS with remote selective targeting produces focal and robust signals that may enable sustained relief without permanent implantation

Remote selective targeting PNS enables selective activation of target sensory fibers and produces more focal and robust signals from the periphery to the CNS. As shown in the figure below representing the proposed cortical effects of remote selective targeting, the red region in the cortex (left) represents an area of maladaptive plasticity contributing to chronic pain. During treatment, pain-reducing signals are produced that are robust (i.e., are produced by selectively activating a large number of target sensory fibers) and are focal to the region of pain. These signals (middle; represented in green) result in reconditioning of the cortex during the 60-day treatment such that the maladaptive plasticity is no longer present and pain relief is maintained post-treatment (right).

Cortical Effects 60-Day PNS
  • The red region in the cortex represents an area contributing to chronic pain (left)
  • During treatment the cortex receives focal and robust non-nociceptive signals (green, middle) generated by remote selective targeting PNS for 60 days
  • Continuous stimulation is not required to support pain relief
  • Remote selective targeting PNS produces focal and robust non-nociceptive signals
  • Sustained pain relief without permanent implantation may be enabled (right)

Whereas remote selective targeting PNS produces focal and robust signals, conventional PNS is often limited

In comparing the techniques of conventional PNS with remote selective targeting PNS, the review by Deer et al. found that conventional PNS is not designed to meet the required conditions to effectively recondition the CNS and therefore typically requires continuous stimulation from implanted devices to support long-term pain relief.

Conventional PNS requires continuous stimulation for sustained pain relief

In the graphic below, the red highlighted portion again represents maladaptive cortical plasticity that contributes to chronic pain (left). When conventional PNS is active, the target sensory fibers can produce comfortable pain-relieving sensations (middle; shown in green). While these signals are focal in the region of pain, they are not robust enough to recondition the CNS and so the maladaptive CNS changes associated with chronic pain remain when stimulation ends (right), and pain relief is short-lived in the absence of continuous stimulation. Additionally, with conventional PNS, the review also noted that increasing stimulation intensity in an attempt to produce more robust signals often produces unintended discomfort (e.g., motor or pain fiber activation).

Cortical Effects Conventional PNS
  • Continuous stimulation is required to support pain relief with conventional PNS
  • Conventional PNS-generated signals are insufficient to recondition the CNS, allowing pain to return when stimulation is turned off
  • To support sustained pain relief with conventional PNS, a permanently implanted system is typically necessary

Conclusion: PNS with Remote Selective Targeting May Enable Reconditioning of the Cortex Necessary to Produce Sustained Chronic Pain Relief

Based on the review of the techniques, technology, and peripheral and cortical effects of both conventional and remote selective targeting PNS approaches, we concluded with the following theory: remote selective targeting may enable sustained pain relief without a permanent PNS system implant by reconditioning the CNS during a short-term (e.g., 60-day) treatment.

In closing, based on our review we see the potential of percutaneous PNS to offer patients a non-permanent treatment option with sustainable pain relief results. 

Study authors: Timothy Deer, MD, Sam Eldabe, MD, Steven Falowski, MD, Marc Huntoon, MD, Peter Staats, MD, Isaac Cassar, Nathan Crosby, PhD, and Joseph Boggs, PhD

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: 60-day percutaneous PNS, Chronic Pain, Cortical Effect, pain treatment, peripheral nerve stimulation, PNS, recondition CNS, SPRINT PNS
Previous Post:Researchers Unveil a New Theory Explaining Long-term Pain Relief
Next Post:The Impact of COVID-19 on Chronic Pain and Stress: A Discussion with Dr. Mehul Desai

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference

SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo